BWXT Announces Availability of FDA-Approved Indium In-111 Oxyquinoline Solution
(LYNCHBURG, Va. – September 26, 2019) – BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.
BWXT Signs Medical Isotope Development Agreement with Bruce Power
(LYNCHBURG, Va. – July 12, 2018) – BWX Technologies, Inc. (NYSE:BWXT) announced today that a subsidiary has signed an agreement with Bruce Power that will enable the two companies to collaborate on the development and supply of medical isotopes.
BWXT Selects Ontario Power Generation to Provide Irradiation Services for New Medical Isotope Manufacturing Technology
BWX Technologies, Inc. is expanding its longstanding relationship with Ontario Power Generation (OPG), whose wholly owned subsidiary Canadian Nuclear Partners (CNP) plans to provide irradiation services to support BWXT’s new medical isotope manufacturing technology for molybdenum-99.
BWXT Announces Breakthrough Medical Isotope Manufacturing Technology
BWX Technologies, Inc. announced today that it has developed an innovative and unique process to manufacture molybdenum-99 (Mo-99) that will enable a stable, North American supply of this critical diagnostic imaging radionuclide.